Q SYNTHESIS LLC
  • Quality Improvement
  • Systems Thinking
  • Implementation Science
  • Publications
  • About
  • Contact
  • Updates

AJCP article: biomarker testing navigator

5/8/2025

0 Comments

 
Picture

Pineault L, Valencia K, Buhay J, Brown A, Ziemnik S, Kelly M, Morgante J, Datta Mitra A, Yanamura L, Gilliland M, Ferea A, Kim J. ASCP explores the cancer biomarker testing navigator as a novel role to improve laboratory operations and workflows: A special report from the ASCP Biomarker Testing Navigator Project Team. Am J Clin Pathol. 2025 May 7:aqaf028.
doi: 10.1093/ajcp/aqaf028. Epub ahead of print. PMID: 40329479.
doi.org/10.1093/ajcp/aqaf028

​

0 Comments

HER2-low and HER2-ultralow breast cancer resources

5/2/2025

0 Comments

 
ASCP has recently developed several CME activities on the topic of HER2-low and HER2-ultralow breast cancer:

Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: IHC Testing and Interpretation
Link: https://store.ascp.org/productlisting/productdetail?productId=176966209

Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Emerging Science and Current Treatment
Link: https://store.ascp.org/productlisting/productdetail?productId=176989985

Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Reproducibility of Testing
Link: https://store.ascp.org/productlisting/productdetail?productId=176990098
​

0 Comments

2025 Alliance Award: Outstanding Outcomes in CE

1/13/2025

 
Congratulations to the collaborative efforts of ASCP and Q Synthesis for winning the 2025 Award for Outstanding Outcomes in CE Assessment! The project: “Building Knowledge and Skills in Biomarker Testing and Assessment of Pathological Response to Improve Care for Patients with Non-Small Cell Lung Cancer and Melanoma” was supported by an educational grant from BMS.

Picture

The Joint Commission and NAHQ form strategic alliance

11/19/2024

0 Comments

 
The Joint Commission and the National Association for Healthcare Quality Form Strategic Alliance to Advance Global Patient Safety and Healthcare Quality

(CHICAGO and OAKBROOK TERRACE, Illinois, November 19, 2024) – The Joint Commission and the National Association for Healthcare Quality (NAHQ) announce a strategic alliance to advance global healthcare Quality and safety for all.

The alliance stems from a shared vision for safe, high-quality and equitable healthcare between NAHQ, the industry leader in defining Quality competencies and developing and certifying the healthcare Quality workforce, and The Joint Commission, the world’s premier and most recognized brand in standards-setting and accrediting body in healthcare.

Read more about this here:
www.jointcommission.org/resources/news-and-multimedia/news/2024/11/the-joint-commission-and-nahq-form-strategic-alliance/
0 Comments

Obesity QI poster presented at ObesityWeek 2024

11/13/2024

 
Obesity Change Makers: National Quality Improvement Initiative to Improve Evidence-Based Care​
Presented at ObesityWeek 2024 

Learn more about this project here: clinicaloptions.com/content/qi-obesity

QI Toolkit: clinicaloptions.com/activities/endocrinology-diabetes-metabolism/obesity-qi-tool-kit/17391-24775/info
​

Abstracts from ASCP 2024

10/29/2024

 
Preparing the Laboratory for Neoadjuvant Cancer Immunotherapy: Insights from a Pathology Learning Collaborative
American Journal of Clinical Pathology, Volume 162, Issue Supplement_1, October 2024, Page S125
doi.org/10.1093/ajcp/aqae129.277

Assessing the Feasibility of a Cancer Biomarker Testing Navigator in the Laboratory
American Journal of Clinical Pathology, Volume 162, Issue Supplement_1, October 2024, Page S122
doi.org/10.1093/ajcp/aqae129.270

Impact of a PD-L1 Learning Collaborative: outcomes from a mixed-methods evaluation
American Journal of Clinical Pathology, Volume 162, Issue Supplement_1, October 2024, Pages S143–S144
doi.org/10.1093/ajcp/aqae129.319

Integrating Biomarker Testing into EHR Systems: Implications for the Laboratory Based on Findings from a Multistakeholder Summit
American Journal of Clinical Pathology, Volume 162, Issue Supplement_1, October 2024, Page S101
doi.org/10.1093/ajcp/aqae129.225
​

Learn about pan-tumor HER2 testing in advanced solid tumors

10/24/2024

0 Comments

 
ASCP has released 3 CME activities to cover recent updates on pan-tumor HER2 testing in advanced solid tumors.

Updates in HER2-directed Therapies in Solid Tumors
https://store.ascp.org/productlisting/productdetail?productId=173008379
 
HER2 Testing in Gynecologic Cancers and Implications for Treatment
https://store.ascp.org/productlisting/productdetail?productId=173041833
 
HER2 Testing in Other Solid Tumors and Implications for Treatment 
https://store.ascp.org/productlisting/productdetail?productId=173042038
​
0 Comments

Another CME Tweetorial covering pan-tumor HER2 testing in advanced solid tumors!

9/30/2024

 
Scroll down to read each Tweet of this CME Tweetorial on pan-tumor HER2 testing!

Click on each Tweet below to open on Twitter:
x.com/ASCP_Chicago/status/1840785569023995962

​Claim CME here: store.ascp.org/productlisting/productdetail?productId=172789750

2/18 HER2 now joins other tumor-agnostic biomarkers like MSI/MMR, Tumor Mutation Burden (TMB), NTRK, RET, BRAF V600E. Different testing methods such as IHC or NGS will detect different biomarkers.https://t.co/NjXRR6iOMx#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

4/18 HER2 is also called ERBB2. Testing by IHC detects HER2 expression while molecular testing by NGS detects HER2 amplification or activating mutations. HER2 expression and HER2 activating mutations are distinct molecular targets.#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

6/18 T-DXd is the first antibody drug conjugate (ADC) with a tumor agnostic approval to treat advanced solid tumors with HER2 overexpression (IHC 3+).https://t.co/7vohZuTuFW#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

8/18 Tumor heterogeneity can make HER2 interpretation challenging. Here’s an example of intratumoral HER2 heterogeneity. https://t.co/Cig40jNdv0#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

10/18 HER2 scoring criteria for gastric and GE cancers were published in 2016. Note the differences for biopsy vs. surgical specimens. https://t.co/97xeDbDoHV #HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

12/18 NGS may detect HER2 amplification. Most tumors with HER2 overexpression are likely to also exhibit HER2 amplification. https://t.co/SCQYvJqoyE#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

14/18 Here’s a table that lists how often we may see HER2 mutations, HER2 amplification, and HER2 overexpression in different tumors:https://t.co/rmlRr7CE1B#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024

16/18 While IHC remains the clinical standard for pan-tumor HER2 testing, alternative methods are also being explored. Moreover, a growing area of research is detecting low levels of HER2 expression. This is clinically actionable in metastatic breast cancer.…

— ASCP (@ASCP_Chicago) September 30, 2024

18/18 Thank you for participating in this ASCP CME Tweetorial on pan-tumor HER2 testing! Claim your CME credit here: https://t.co/MJ8OJzFLhl#HER2 #PathTwitter #pathx #pantumor

— ASCP (@ASCP_Chicago) September 30, 2024
Claim CME here: store.ascp.org/productlisting/productdetail?productId=172789750

Precision Oncology CME Activities

9/18/2024

 
Here are a series of online CME/CE activities covering cancer biomarker testing and precision oncology in patients with actionable genomic alterations:
clinicaloptions.com/program/oncology/reshaping-care-biomarker-testing-in-solid-tumors/28010
  • Reshaping Cancer Care: Current Best Practices for Precision Medicine in Patients With Advanced Solid Tumors
  • Test Your Skills: Understanding the Current Biomarker Landscape for Patients With Advanced Colorectal Cancer
  • Test Your Skills: Individualizing Treatment for Patients With Advanced NSCLC
  • Test Your Skills: The Importance of Biomarker Testing for Patients With Advanced NSCLC
  • Test Your Skills: Understanding the Current Biomarker Landscape for Patients With Medullary Thyroid Cancer
​

CME Tweetorial on pan-tumor HER2 Testing

9/17/2024

 
Twitter (X) for CME! 

Here is a CME Tweetorial on the topic of pan-tumor HER2 in advanced gynecologic cancers. Read through these threaded tweets: x.com/ASCP_Chicago/status/1826660024975782312

Claim CME credit here: t.co/iJjqlWc47f​

Rate your level of familiarity with pan-tumor HER2 biomarker testing in patients with advanced solid tumors.#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Investigator-assessed ORRs (objective response rate) was 57.5% for endometrial (95% CI, 40.9 to 73.0); 50.0% for cervical (95% CI, 33.8 to 66.2); 45.0% for ovarian (95% CI, 29.3 to 61.5) in DESTINY-PanTumor02. https://t.co/IX3C4o1kjY#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

ADCs like T-DXd have unique toxicity profiles. Vigilant monitoring required for patients receiving treatment. https://t.co/yzi8aQo1FP#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Differences in HER2 overexpression may be observed when using different IHC antibodies in ovarian and endometrial clear cell carcinoma (CCC). https://t.co/GrcjFpZC3C#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

In DESTINY-PanTumor02 the ASCO/CAP guidelines for scoring HER2 in gastric cancer were used to assess results. https://t.co/g61yYDb9J7#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Read this article that outlines some practical considerations when implementing a pan-tumor HER2 IHC test in the laboratory: https://t.co/vYAP1Uq29J#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Patients with advanced HER2-positive (IHC 3+) cervical, endometrial, and ovarian cancers may be considered for treatment based on the FDA accelerated approval of T-DXd for this indication. https://t.co/EtEWxs0INY#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024

Thank you for participating in this CME Tweetorial on pan-tumor HER2 testing! Claim your CME credit here: https://t.co/fLFjXx0Gur

Stay tuned as ASCP releases more education on this topic in the coming months!#HER2 #PathTwitter #GYNPATH #pathx

— ASCP (@ASCP_Chicago) August 22, 2024
<<Previous

    Author

    @DrJosephKim
    Joseph Kim, MD, MPH, MBA, FACEHP is the Founder and President of Q Synthesis LLC.

    ​View Dr. Kim's bio on LinkedIn. 

    ​


    Sign up to receive updates:
Q Synthesis LLC
Home

About

Contact
​

​Publications
Picture
​Quality Improvement 
​
Systems Thinking 

​Implementation Science 

​Updates
www.qsynthesis.com
  • Quality Improvement
  • Systems Thinking
  • Implementation Science
  • Publications
  • About
  • Contact
  • Updates